Special Issue "Antivirals Against Influenza"

Quicklinks

A special issue of Viruses (ISSN 1999-4915).

Deadline for manuscript submissions: closed (30 April 2010)

Special Issue Editor

Guest Editor
Dr. Megan Shaw
Department of Microbiology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1124, New York, NY 10029, USA
E-Mail:
Phone: Office: +1 212 241 8931; Lab: +1 212 241 3466
Fax: +1 212 534 1684

Published Papers

Special Issue Information

Dear Colleagues,

Influenza continues to be a major health problem worldwide due to the constant mutation of circulating viruses and the possible emergence of a new influenza virus. This was emphasized by the declaration of an influenza pandemic in 2009 following the introduction of a novel H1N1 virus into the human population. For both seasonal and pandemic influenza, the availability of effective influenza antiviral drugs is critical for both therapeutic and prophylactic use. There are currently two classes of FDA-approved drugs for treating influenza infections. These are the neuraminidase inhibitors (oseltamivir, zanamivir and peramivir) and the M2 ion channel inhibitors (amantadine and rimantadine). Widespread resistance to the M2 inhibitors, caused by mutations in the M2 protein, has reduced their effectiveness and consequently neuraminidase inhibitors are usually the recommended therapy. However, rapid emergence of oseltamivir resistance amongst the seasonal H1N1 viruses has given cause for concern and clearly indicates that new drugs and/or new approaches are urgently required.

In this special issue on “Antivirals Against Influenza”, the authors provide perspective on recent studies that address resistance to the current antivirals, options for combination therapies, new antiviral candidates in development and the availability of suitable animal models for ascertaining efficacy.

Dr. Megan Shaw
Guest Editor

Submission

All manuscripts should be submitted to viruses@mdpi.com with a copy to the Guest Editor. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues, to be published in 2009 and 2010, the Article Processing Charges (APC) in this Open Access journal will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

Last update: 13 January 2012

Viruses EISSN 1999-4915 Published by MDPI Publishing, Basel, Switzerland RSS E-Mail Table of Contents Alert